Clinical Trial: Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Op

Brief Summary:

Patent ductus arteriosus (PDA) is a common problem in preterm babies. Recently there have been various studies for and against an association between thrombocytopenia and PDA. A meta-analysis published in 2015 showed a marginally significant positive association between PDA and thrombocytopenia but these were all observational studies and there are no randomized controlled trials (RCT) on it. The investigators decided to conduct an RCT to determine whether liberal platelet transfusion criteria achieve earlier PDA closure rates than standard restrictive platelet transfusion criteria among thrombocytopenic preterm neonates (<35 weeks' gestation) with hemodynamically significant PDA presenting within the first 14 days of life. The investigators primary objective is to determine whether liberal platelet transfusion criteria achieve earlier PDA closure rates within 120 hours compared to standard restrictive platelet transfusion criteria among thrombocytopenic preterm neonates (<35 weeks' gestation) with hemodynamically significant PDA presenting within the first 14 days of life.

The investigators will stratify the study population based on platelet count, i.e < 50000 and 50000-100000 per microlitre, and will randomly allocate participants to control and intervention group. Babies in the intervention group will receive platelet transfusion to maintain the platelet count above 100,000 per microlitre. Babies in control group will receive platelets only when clinically indicated and as per current standard indications. The investigators will perform an echocardiogram at baseline to document a hemodynamically significant PDA (hsPDA) and then serially to look for the closure of PDA. Medical management of PDA will be as per unit policy. The investigators will follow the baby till PDA closes or 120 hours post randomization.


Detailed Summary:

Study Background:

Preterm babies are a unique group of patients in Newborn Intensive Care Unit. Patent ductus arteriosus (PDA) is a common complication related to the gestational age of preterm birth. In infants born at less than 32 weeks of gestation, the frequency of PDA has been reported from 50% to 80%. Physiologic ductus arteriosus closure occurs in the first 3 days after birth. The persistence of a PDA beyond the first postnatal days of life, however, is frequently associated with multiple severe complications, predominantly in the most immature infants It is currently believed that ductus arteriosus (DA) closure involves a two-step process. The first, 'provisional' closure is accomplished by smooth muscle cell contraction and ductus arteriosus (DA) constriction. Subsequently, the proliferation of cells within the former DA lumen leads to anatomical remodeling of the DA and permits permanent closure. Recently an association between the absolute platelet count and the closure of ductus arteriosus has been the focus of research. Various prospective and retrospective studies have been conducted for the same. In 2015 systematic review and meta-analysis by Sorina et al showed a significant positive association between PDA and thrombocytopenia. Hence the investigators planned randomized controlled trial to look for the effect of platelet transfusion on closure rates of ductus arteriosus.

Research question:

Do liberal platelet transfusion criteria achieve earlier PDA closure rates than standard restrictive platelet transfusion criteria among thrombocytopenic preterm neonates (<35 weeks gestation) with hemodynamically significant PDA presenting within the first 14 days of life?

Objectives:

Time point at which closure (Absence of flow in PDA on colour doppler) is documented first time will be considered as time to closure of PDA



Original Primary Outcome: Time to closure of PDA post randomization [ Time Frame: within 120 hours post randomisation ]

Current Secondary Outcome:

  • Proportion of participants in whom PDA is open [ Time Frame: at 120 hours after randomization ]
    PDA will be considered open if there is presence of flow on colour doppler
  • Proportion of participants in whom PDA is echocardiographically hemodynamically significant [ Time Frame: at 120 hours after randomization ]
    hemodynamic significance is defined somewhere else in text
  • Cumulative volume of platelet concentrate received [ Time Frame: within 120 hours after randomization ]
    Total volume in ml/kg will be recorded
  • Number of participants with Clinical bleed of any kind ( defined below) [ Time Frame: within 120 hours after randomization ]
    Any visible fresh oral, nasal, endotracheal, gastrointestinal or skin bleed will be considered as clinical bleed.
  • New onset IVH of any grade [ Time Frame: within 120 hours after randomization ]
    Cranial ultrasound will be done as per protocol to look for IVH
  • New onset IVH of grade 3or 4 [ Time Frame: within 120 hours after randomization ]
    Cranial ultrasound will be done as per protocol to look for IVH
  • Mortality [ Time Frame: within 120 hours after randomization ]
    It stands for all cause mortality
  • Mortality [ Time Frame: All subjects will be part of the study until death or discharge from the hospital. Timeframe for measuring mortality as an outcome is from the point of randomisation through the study period which will be approximately upto 30 days post randomisation ]
    It stands for all cause mortality
  • Duration of hospital stay [ Time Frame: All subjects will be part of the study until death or discharge from the hospital.Timeframe for measuring duration of hospital stay is from the point of randomisation through the study period which will be approximately upto 30 days post randomisation ]
    Duration of stay will be from date of birth to date of discharge/referral or death
  • Reopening rate of PDA that had initially closed [ Time Frame: within 120 hours of randomization ]
    It will include situation where PDA closure was documented on two consecutive occasions 24 hours apart and then at later stage it opens.


Original Secondary Outcome:

  • Proportion of participants in whom PDA is open [ Time Frame: at 120 hours after randomization ]
  • Proportion of participants in whom PDA is echocardiographically hemodynamically significant [ Time Frame: at 120 hours after randomization ]
  • Cumulative volume of platelet concentrate received [ Time Frame: within 120 hours after randomization ]
  • Number of participants with Clinical bleed of any kind ( defined below) [ Time Frame: within 120 hours after randomization ]
    Any visible fresh oral, nasal, endotracheal, gastrointestinal or skin bleed will be considered as clinical bleed.
  • New onset IVH of any grade [ Time Frame: within 120 hours after randomization ]
  • New onset IVH of grade 3or 4 [ Time Frame: within 120 hours after randomization ]
  • Mortality [ Time Frame: within 120 hours after randomization ]
  • Mortality [ Time Frame: All subjects will be part of the study until death or discharge from the hospital. Timeframe for measuring mortality as an outcome is from the point of randomisation through the study period which will be approximately upto 30 days post randomisation ]
  • Duration of hospital stay [ Time Frame: All subjects will be part of the study until death or discharge from the hospital.Timeframe for measuring duration of hospital stay is from the point of randomisation through the study period which will be approximately upto 30 days post randomisation ]
  • Reopening rate of PDA that had initially closed [ Time Frame: within 120 hours of randomization ]


Information By: Postgraduate Institute of Medical Education and Research

Dates:
Date Received: June 25, 2016
Date Started: March 2016
Date Completion: June 2017
Last Updated: April 26, 2017
Last Verified: April 2017